REGENXBIO Inc. (RGNX): Results of Operations and Financial Condition
REGENXBIO Inc. (RGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights • RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 • Long-term surabgene lomparvovec (sura-vec, AB
How this was made
The 30-second read
Why it matters
The filing provides fresh, time-stamped catalysts: RGX-202 Phase 3 primary endpoint success, FDA reaffirmation for RGX-121 BLA resubmission with Q3 2026 timing, first dosing in NAAVIGATE with a $100M AbbVie milestone, and a cash runway extension into Q4 2027 via $200M+ new capital.
Market read
Traders can update catalyst-driven positioning around Q3 2026 BLA initiation and Q4 2026 wet AMD pivotal topline, supported by disclosed cash runway and milestone funding.
What to watch
The wet AMD pivotal topline is not yet reported (only expected in Q4 2026), and the Phase 3 endpoint is based on interim reporting details (e.g., NSAA n=9) that may not fully de-risk commercialization.
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
Revenue and net income improved substantially, supported by a $100.0 million development milestone tied to NAAVIGATE enrollment, while R&D expense declined. The company also reported clinical and regulatory progress across RGX-202, sura-vec and RGX-121, and July financing extended expected cash runway into Q4 2027.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenuesGAAP | $108.0 million | – | – |
| ZOLGENSMA royalty revenues decreaseGAAP | $16.7 million decrease | – | – |
| Research and development expensesGAAP | $56.1 million | – | – |
| General and administrative expensesGAAP | $21.6 million | – | – |
| Net incomeGAAP | $22.7 million | – | – |
| Basic net income per shareGAAP | $0.43 basic net income per share | – | – |
| Diluted net income per shareGAAP | $0.43 diluted net income per share | – | – |
| Cash, cash equivalents and marketable securitiesother | $105.5 million | – | – |
| Pro forma cash, cash equivalents and marketable securities as of June 30, 2026other | approximately $313 million | – | – |
| AbbVie milestone payment received in July 2026other | $100 million | – | – |
| Estimated net proceeds from underwritten public offering received in July 2026other | approximately $108 million | – | – |
into Q4 2027 outlook
- NoteREGENXBIO expects its balance in cash, cash equivalents and marketable securities of $105.5 million as of June 30, 2026, along with the $100.0 million milestone payment and $107.8 million estimated net offering proceeds received in July 2026, are sufficient to fund operations into Q4 2027.
- NoteCash runway guidance excludes the impact of any material payments that may potentially be received from partners or licensees upon the achievement of development or regulatory milestones, or upon the approval or commercialization of product candidates, and excludes any additional potential dilutive or non-dilutive funding opportunities.
- NoteRGX-202 BLA submission is on track for Q3 2026 under the accelerated approval pathway, supporting potential approval in 2H 2027.
- NoteREGENXBIO expects to initiate AFFINITY RISE in 1H 2027.
- NoteTopline data from the ATMOSPHERE and ASCENT pivotal trials are expected in Q4 2026.
- NoteGlobal regulatory submissions for sura-vec are expected in 2027.
- NoteREGENXBIO plans to resubmit the RGX-121 BLA in Q3 2026.
What drove it
- The increase in revenues was primarily attributable to the $100.0 million development milestone achieved in the second quarter of 2026 upon dosing the first patient in the NAAVIGATE study.
- The revenue increase was partially offset by a $16.7 million decrease in ZOLGENSMA royalty revenues due to the expiration of licensed patents in the U.S. in January 2026.
- R&D expense declined primarily because of manufacturing-related expenses and clinical trial expenses for sura-vec and NAVSUNLI pivotal trials.
- General and administrative expense increased largely due to personnel-related costs, commercialization expenses, consulting and other corporate advisory services.
- The Phase III AFFINITY DUCHENNE trial met its primary endpoint with high statistical significance (p<0.0001).
- The confirmatory study of RGX-202 completed enrollment in June 2026 ahead of schedule due to strong patient demand and robust investigator interest.
- The FDA reaffirmed during a July 2026 Type A meeting that no additional studies of RGX-121 are required for the BLA resubmission.
Concerns
- Cash, cash equivalents and marketable securities declined to $105.5 million as of June 30, 2026 from $240.9 million as of December 31, 2025.
- The ZOLGENSMA royalty revenue decrease was attributed to the expiration of licensed patents in the U.S. in January 2026.
- Cash runway guidance excludes potential partner or licensee payments and additional potential dilutive or non-dilutive funding opportunities.
- The reported revenue increase was primarily attributable to a $100.0 million development milestone.
What to watch
- Initiation of the RGX-202 BLA submission in Q3 2026 and potential approval in 2H 2027.
- RGX-121 BLA resubmission in Q3 2026.
- Topline ATMOSPHERE and ASCENT pivotal wet AMD data in Q4 2026.
- Initiation of the ex-U.S. AFFINITY RISE study in 1H 2027.
- Progress of the Phase IIb/III NAAVIGATE study for diabetic retinopathy.
- Execution against expected cash runway into Q4 2027.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $105.5 million as of June 30, 2026, compared to $240.9 million as of December 31, 2025.
- The decrease was primarily driven by cash used to fund operating activities during the first half of 2026.
- In July 2026, REGENXBIO received a $100 million milestone payment from AbbVie and approximately $108 million estimated net proceeds from an underwritten public offering of common stock and pre-funded warrants.
- Pro forma cash, cash equivalents and marketable securities as of June 30, 2026 was approximately $313 million.
Analysis
REGENXBIO reported $108.0 million of revenue for the three months ended June 30, 2026, compared with $21.4 million for the three months ended June 30, 2025. The company attributed the increase primarily to a $100.0 million development milestone achieved upon dosing the first patient in the NAAVIGATE study. The gain was partially offset by a $16.7 million decline in ZOLGENSMA royalty revenues following the expiration of licensed U.S. patents in January 2026. Net income was $22.7 million, or $0.43 basic and diluted net income per share, compared with a net loss of $70.9 million, or $1.38 basic and diluted net loss per share, in the prior-year period.
The cost profile improved in R&D but increased in G&A. R&D expenses were $56.1 million compared with $59.5 million, with the decline attributed to manufacturing-related and clinical trial expenses for sura-vec and NAVSUNLI pivotal trials. General and administrative expenses were $21.6 million compared with $19.9 million, driven largely by personnel-related costs, commercialization expenses, consulting and other corporate advisory services. The filing does not report gross profit, gross margin, operating income or operating margin.
Clinical execution was the principal operating highlight. The Phase III AFFINITY DUCHENNE trial met its primary endpoint with high statistical significance (p<0.0001), and the RGX-202 confirmatory study completed enrollment in June 2026 ahead of schedule. The company remains on track to initiate an RGX-202 BLA submission in Q3 2026 under the accelerated approval pathway. In retinal disease, the first NAAVIGATE participant was dosed in June 2026, triggering the AbbVie milestone, while topline data from the ATMOSPHERE and ASCENT pivotal wet AMD trials are expected in Q4 2026. For RGX-121, the FDA reaffirmed in a July 2026 Type A meeting that no additional studies are required for the planned Q3 2026 BLA resubmission.
Liquidity was reinforced after quarter-end. Cash, cash equivalents and marketable securities were $105.5 million as of June 30, 2026, compared with $240.9 million as of December 31, 2025, with the decline primarily driven by cash used in operating activities during the first half of 2026. In July, REGENXBIO received a $100 million AbbVie milestone payment and approximately $108 million of estimated net offering proceeds. Pro forma cash, cash equivalents and marketable securities as of June 30, 2026 were approximately $313 million, and management expects available funds to support operations into Q4 2027. The runway assumption excludes potential partner payments and any additional potential dilutive or non-dilutive funding opportunities.
Management, verbatim
Our second quarter was defined by strong clinical execution across our pipeline: the Phase III AFFINITY DUCHENNE ® trial met its primary endpoint, we dosed the first participant in the NAAVIGATE study in diabetic retinopathy, and the FDA reaffirmed the path forward for RGX-121.
Curran Simpson, President and Chief Executive Officer
Not in the filing
stated, not guessed- Gross profit
- Gross margin
- Operating income or loss
- Operating margin
- Non-GAAP revenue, earnings, EPS or expense metrics
- Prior-quarter revenue, expenses, net income or EPS
- Percentage year-over-year and quarter-over-quarter changes for reported financial metrics
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt and debt maturities
- Share repurchases
- Dividends
- Segment revenue and segment profitability
- Quantified revenue, gross-margin, operating-expense or tax-rate guidance
- Prior outlook for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is REGENXBIO’s SEC Form 8-K (Item 2.02) with Q2 2026 financial results and operational milestones across its Duchenne (RGX-202), wet AMD/DR (sura-vec), and Hunter syndrome (RGX-121) programs.
Ticker impact
REGENXBIO reports Q2 results and says RGX-202 Duchenne Phase 3 met its primary endpoint, with RGX-202 BLA initiation targeted for Q3 2026.
Bias toward upside as investors price in BLA timing and upcoming pivotal readouts, though dilution/cash burn risk remains.
The filing discloses multiple time-bound, decision-relevant events: Phase 3 endpoint achievement, FDA Type A reaffirmation for RGX-121 resubmission, first patient dosing in NAAVIGATE with a $100M milestone, and a cash runway extension into Q4 2027.
Market effects
Reinforces investor appetite for gene-therapy timelines tied to FDA accelerated-approval pathways and durable efficacy/safety narratives.
Limited, primarily US biotech sentiment via Nasdaq-listed catalyst calendar.
AbbVie collaboration and ex-US regulatory submission plans can influence broader global retina/gene-therapy expectations.
Counterpoint
Despite strong clinical and FDA process updates, the cash balance fell materially in H1 2026, so future financing risk could cap upside.
Key entities
- companyREGENXBIO Inc.
Nasdaq-listed gene therapy developer reporting Q2 2026 results and multiple near-term regulatory and clinical catalysts.
- partnerAbbVie
Collaboration partner providing a $100M milestone tied to NAAVIGATE first patient dosing and co-development for sura-vec.
- regulatorFDA
Held a Type A meeting for RGX-121, reaffirming no additional studies required for BLA resubmission.
